BioSpace News Archive

Series of preclinical studies demonstrate the therapeutic potential of CY6463, a first-in-class, CNS-penetrant sGC stimulator Oral, once-daily CY6463 is being developed for neurological diseases associated with cognitive impairment

Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapeutics to address difficult to treat oncology indications, announced today that it has entered into a Collaboration Agreement with the National Cancer Institute (NCI) of the National Institutes of Health (NIH)

Disc Medicine, Inc. announced today that it has entered into an exclusive worldwide licensing agreement with F. Hoffmann-La Roche Ltd for the development and commercialization of bitopertin, an orally administered GlyT1 inhibitor with demonstrated effects on the heme biosynthesis pathway.

The Government of Canada welcomes the report on border testing and quarantine measures from the COVID-19 Testing and Screening Expert Advisory Panel, issued on May 27, 2021, and thanks the members for their important work

ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the Jefferies Virtual Healthcare Conference 2021 as follows: Date: Friday, June 4, 2021 Time: 10:00 a.m. ET

Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that its Board of Directors has approved a $3.0 million stock repurchase authorization, effective as of May 26, 2021.

Nautilus Biotechnology, Inc. (“Nautilus Biotechnology” or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the human proteome, today announced the company will be participating in the upcoming Goldman Sachs 42nd Annual Global Healthcare Conference. Nautilus’ management is scheduled to present on Thursday, June 10th at 3:00 p.m. Eastern Time/12:00 p.m. Pacific Time.

IRVINE, CA, and HERSTAL, BELGIUM – 27 May 2021 – MDxHealth SA a commercial-stage innovative molecular diagnostics company, held its annual general shareholders’ meeting and an extraordinary general shareholders’ meeting

Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company participated in a late-cycle meeting with the U.S. Food and Drug Administration (“FDA”) yesterday.

Illumina, Inc. announced that its executives will be speaking at the following investor conference